WooGene B&G Co., Ltd (KOSDAQ:018620)
2,720.00
+5.00 (0.18%)
At close: Sep 11, 2026
WooGene B&G Revenue
WooGene B&G had revenue of 15.49B KRW in the quarter ending June 30, 2026, with 12.71% growth. This brings the company's revenue in the last twelve months to 56.49B, up 6.10% year-over-year. In the year 2025, WooGene B&G had annual revenue of 54.76B, down -1.65%.
Revenue (ttm)
56.49B
Revenue Growth
+6.10%
P/S Ratio
0.33
Revenue / Employee
570.65M
Employees
99
Market Cap
18.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.76B | -915.98M | -1.65% |
| Dec 31, 2024 | 55.68B | -2.24B | -3.87% |
| Dec 31, 2023 | 57.92B | 14.22B | 32.53% |
| Dec 31, 2022 | 43.70B | 4.36B | 11.07% |
| Dec 31, 2021 | 39.35B | -176.99M | -0.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 94.89B |
| ChoA Pharmaceutical Co., LTD. | 61.16B |
| CXI Healthcare Technology Group | 51.45B |
| Seoul Pharma | 51.08B |
| Union Korea Pharm | 25.45B |
| Daesung Microbiological Labs. | 25.20B |
| BIFIDO | 14.63B |
| Pharmsville | 11.20B |